Health and Fitness Health and Fitness
Mon, March 14, 2011
Sun, March 13, 2011
Sat, March 12, 2011
Fri, March 11, 2011

NuPathe to Present at the Roth 23rd Annual OC Growth Stock Conference


Published on 2011-03-11 09:16:03 - Market Wire
  Print publication without navigation


CONSHOHOCKEN, PA--(Marketwire - March 11, 2011) - NuPathe Inc. (NASDAQ: [ PATH ]), a specialty pharmaceutical company focused on the development and commercialization of branded therapeutics for diseases of the central nervous system, including neurological and psychiatric disorders, today announces that [ Jane Hollingsworth ], chief executive officer, will present a company overview at the Roth 23rd Annual OC Growth Stock Conference on Tuesday, March 15, 2011 at 7:30 p.m. EDT. The conference is being held at The Ritz Carlton in Laguna Niguel, CA.

A live audio webcast of the presentation will be available via the "Investor Relations" page of the NuPathe website, [ www.nupathe.com ]. Please log on through NuPathe's website approximately 10 minutes prior to the scheduled start time. A replay of the webcast will also be archived on the Company's website for 90 days following the call.

About NuPathe

NuPathe Inc. ([ www.nupathe.com ]) is a specialty pharmaceutical company focused on the development and commercialization of branded therapeutics for diseases of the central nervous system, including neurological and psychiatric disorders. NuPathe's most advanced product candidate, [ Zelrix ], is a single-use, transdermal sumatriptan patch being developed for the treatment of acute migraine. In addition to Zelrix, NuPathe has two proprietary product candidates in preclinical development: [ NP201 ] for the continuous symptomatic treatment of Parkinson's disease, and [ NP202 ] for the long-term treatment of schizophrenia and bipolar disorder.